Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells

The exact influence of statins on gefitinib resistance in human non-small cell lung cancer (NSCLC) cells with KRAS mutation alone or KRAS/PIK3CA and KRAS/PTEN comutations remains unclear. This work found that transfection of mutant KRAS plasmids significantly suppressed the gefitinib cytotoxicity in...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, J, Bi, H, Hou, J, Zhang, X, Zhang, C, Yue, L, Wen, X, Liu, D, Shi, H, Yuan, J, Liu, J, Liu, B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3789171/
https://www.ncbi.nlm.nih.gov/pubmed/24071646
http://dx.doi.org/10.1038/cddis.2013.312

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3789171/
https://www.ncbi.nlm.nih.gov/pubmed/24071646
http://dx.doi.org/10.1038/cddis.2013.312

Ejemplares similares